Compare Novo Nordisk A/S (NVO) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Impinj Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Impinj Inc trades at $189.55 (market cap $5.60B). The key difference: Novo Nordisk A/S is far larger — about 29.5× Impinj Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Impinj Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Impinj Inc for 22 Days on average.
| NVO | PI | |
|---|---|---|
Market Cap | $165.31B | $5.60B |
Volume | 11,432,838 | 9,929 |
Sector | Health | Technology |
52-Week High | $63.98 | $241.91 |
52-Week Low | $35.29 | $91.34 |
Typical Hold Time | 116 Days | 22 Days |
Enterprise Value | $179.56B | $5.73B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Impinj (PI) trades at $189.55, down 0.78% for the day, with strong analyst support showing 16 buy ratings and a $178.83 consensus price target. The stock exhibits bullish technical signals with recent earnings beats in Q1 and Q2 2026, though the company remains unprofitable with negative net margins. Recent news highlights management presentations at investor conferences and upcoming Q3 earnings announcement.
The stock presents growth potential with revenue expansion and strong institutional interest, but faces fundamental challenges with negative profitability and elevated valuation multiples. Key risks include execution on profitability targets and competitive pressures in the RFID chip market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
